TELODENDRIMERS WITH RIBOFLAVIN MOIETIES AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME

• US 20190328742A1
• Filed: 01/19/2018
• Published: 10/31/2019
• Est. Priority Date: 01/19/2017
• Status: Active Grant

• Current Assignee: The Research Foundation for The State University of New York (State University of New York)
• Original Assignee: The Research Foundation for The State University of New York (State University of New York)
• Inventors: LUO, Juntao, GUO, Dandan, SHI, Changying
• Granted Patent: US 11,369,614 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/75 of ethene
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/56 the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: C08G 83/004 After treatment of dendrimers

Abstract

Provided herein are compositions and nanocarriers comprising linear-dendritic telodendrimers (TD) containing riboflavin. The nanocarriers and compositions have desirable loading properties and stabilized structure and can be used for efficient in vivo delivery.

Claims

1. A compound having the following structure:

2. The compound of claim 1, wherein the PEG group has the following structure:

3. The compound of claim 1, wherein D comprises 4 or 8 arginine moieties and each R is

4. The compound of claim 1, wherein the compound is selected from the group consisting of:

5. A composition comprising one or more compounds of claim 1 and methotrexate or an anthracycline.

6. The composition of claim 5, wherein the anthracycline is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, and combinations thereof.

7. The composition of claim 5, wherein the one or more compounds are present as a nanocarrier.

8. The composition of claim 5, wherein for each

9. The composition of claim 5, wherein the composition has a nanocarrier:

methotrexate/anthracycline mass ratio of 1;

1 to 1;

1.6.

10. A method of delivering a therapeutic agent to a subject in need of treatment comprising administering to the subject an effective amount of a composition of claim 5.

11. The method of claim 10, wherein the subject in need of treatment is seeking treatment from the group consisting of inflammation, autoimmune disorders, organ transplants, solid tumors, bone cancer, breast cancer, leukemia, acute lymphocytic, breast cancer, head and neck cancer, leukemia, lung cancer, lymphoma, non-Hodgkin'"'"'s lymphoma, hematological cancer, cervical cancer, bladder cancer, and ovarian cancer.

12. The method of claim 10, wherein for each

13. The method of claim 10, wherein the composition has a nanocarrier:

methotrexate/anthracycline mass ratio of 1;

1 to 1;

1.6.

14. The method of claim 10, wherein the composition provides a dose of 1.5 to 3 times the recommended dose of doxorubicin or a liposomal doxorubicin formulation.

15. A kit comprising:

i) at least one compound of claim 1 and methotrexate, an anthracycline, or a combination thereof; and

ii) a set of instructions, wherein the instructions describe how to use the compound or composition.